Ozempic Gastroparesis Attorney: Understanding the Statute of Limitations in Florida

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Specific Risk Awareness

For decades, general health and science communication has served as the foundation for public understanding of medical treatments and their potential outcomes. This legacy context emphasizes broad awareness of therapeutic benefits while acknowledging that all medications carry inherent risks. Within this framework, the public has been educated to recognize that drug safety profiles evolve as real-world usage expands beyond clinical trials. The transition from general health literacy to specific product exposure concerns follows a natural progression: as medications become widely prescribed, post-market surveillance reveals patterns that warrant focused attention. In the domain of mass production and widespread pharmaceutical distribution, the volume of prescriptions creates a corresponding scale of potential adverse events. When a medication like Ozempic achieves broad utilization for its intended metabolic effects, the manufacturing and supply chain dynamics mean that large populations are simultaneously exposed. This occupational and consumer exposure context shifts the conversation from general health education to specific risk management. The concern now centers on whether the manufacturing scale and distribution patterns have adequately accounted for emerging safety signals, particularly regarding gastrointestinal complications that may manifest over time. This pivot from abstract health literacy to concrete exposure scenarios sets the stage for examining legal timelines and accountability frameworks.

The Medical Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. Clinical diagnosis typically involves gastric emptying scintigraphy or breath testing. The mechanistic link between Ozempic and gastroparesis is biologically plausible: GLP-1 receptor agonists delay gastric motility, and in susceptible individuals, this effect may become pathological, resulting in gastroparesis. Evidence from clinical trials demonstrates a higher incidence of gastrointestinal adverse reactions among patients receiving Ozempic compared to placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions reported in less than 5% of patients include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, adverse reactions reported in at least 5% of Ozempic-treated patients include nausea (placebo 6.1%, 0.5 mg 15.8%, 1 mg 20.3%), vomiting (2.3%, 5.0%, 9.2%), diarrhea (1.9%, 8.5%, 8.8%), abdominal pain (4.6%, 7.3%, 5.7%), and constipation (1.5%, 5.0%, 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse effects, which aligns with the known pharmacology of GLP-1 receptor agonists.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not specifically mention gastroparesis as a potential adverse effect. The label notes that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo and that discontinuation due to these reactions is higher in Ozempic-treated patients. However, the label does not explicitly warn about the risk of developing gastroparesis, which is a more severe and chronic condition. This gap in warning may be relevant for patients who experience persistent symptoms beyond typical nausea and vomiting. For affected patients, attorney-related considerations include evaluating whether the manufacturer provided adequate warnings about the risk of gastroparesis. Patients who developed gastroparesis after using Ozempic may have grounds for a legal claim if they can demonstrate that the manufacturer failed to warn about this specific risk. The timeline between exposure and documented harm is another important factor. In clinical trials, gastrointestinal adverse reactions often occurred during dose escalation, suggesting that symptoms may appear early in treatment. However, gastroparesis can develop after prolonged use, and the latency period may vary among individuals. Patients who used Ozempic for several months or years before developing gastroparesis may need to document the timing of symptom onset relative to drug initiation. Medical records, including prescription dates and symptom diaries, can help establish this timeline.

Florida Statute of Limitations for Ozempic Lawsuits

For patients in Florida, the statute of limitations for filing a product liability lawsuit related to Ozempic and gastroparesis is generally four years from the date of injury or from when the injury was discovered or should have been discovered. This timeframe is governed by Florida Statutes Section 95.11(3). Patients should consult with an attorney promptly to ensure their claim is filed within the applicable limitations period. The statute of limitations may vary depending on the specific circumstances of the case, such as the date of diagnosis and the date when the connection between Ozempic and gastroparesis was recognized. In summary, the evidence supports a mechanistic link between Ozempic and gastroparesis through delayed gastric emptying. Clinical trial data show a higher incidence of gastrointestinal adverse reactions with Ozempic, including symptoms consistent with gastroparesis. The adequacy of warnings is a key risk factor, as the label does not specifically mention gastroparesis. Patients in Florida should be aware of the four-year statute of limitations and seek legal advice to evaluate their options. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for an Ozempic gastroparesis lawsuit in Florida?

In Florida, the statute of limitations for product liability claims, including those related to Ozempic and gastroparesis, is generally four years from the date of injury or from when the injury was discovered or should have been discovered, as per Florida Statutes Section 95.11(3). It is important to consult with an attorney promptly to ensure your claim is filed within this timeframe.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying. This mechanism can lead to gastrointestinal adverse effects, and in some individuals, it may contribute to the development of gastroparesis, a condition characterized by delayed gastric emptying. Clinical trials have shown a higher incidence of gastrointestinal symptoms such as nausea, vomiting, and abdominal pain in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.